All Oncology News

Ruth O’Regan, MD, and Adam M. Brufsky, MD, PhD, FACP, both discuss the emergence of trastuzumab biosimilars in breast cancer.

Francisco J. Esteva, MD, PhD, discusses the cost-saving potential of biosimilars in breast cancer and historical experience with their use.

The FDA has granted an orphan drug designation to durvalumab and tremelimumab for the treatment of patients with hepatocellular carcinoma.

The FDA has granted a priority review designation to a biologics license application for belantamab mafodotin as a treatment for patients with relapsed/refractory multiple myeloma who received prior therapy with an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

The anti–PD-1 agent tislelizumab (BGB-A317) in combination with chemotherapy improved progression-free survival compared with chemotherapy alone as a first-line treatment for patients with advanced squamous non–small cell lung cancer.

Bita Fakhri, MD, discusses data from several recent trials in chronic lymphocytic leukemia and focused on other regimens moving through the pipeline.

Weiyun Z. Ai, MD, PhD, discusses some of the most pivotal advances that have been made in the fields of T-cell lymphoma and Hodgkin lymphoma in recent years.

The FDA has granted a priority review designation to a supplemental new drug application for olaparib (Lynparza) for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or suspected deleterious or somatic homologous recombination repair gene mutations, and who have also progressed on prior therapy with a new hormonal agent.

Neil Dunavin, MD, MS, highlights criteria to consider when approaching treatment selection for patients with myelofibrosis and discussed next steps for the field.

Charalambos (Babis) Andreadis, MD, MSCE, discusses immunotherapeutic advances in MCL and DLBCL based on data from the 2019 ASH Annual Meeting.

Thomas G. Martin, MD, discusses the current treatment approaches in multiple myeloma, as well as the agents that are generating excitement in relapsed/refractory patient populations.

The National Institute for Health and Care Excellence does not recommend larotrectinib for the treatment of advanced NTRK fusion–positive solid tumors in adults and children without satisfactory treatment options.

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses optimal management of adverse events associated with various therapies for patients with melanoma.

Saad Z. Usmani, MD, FACP, discusses the results of the CANDOR trial and the impact of these data on clinical practice in multiple myeloma.

Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.

He James Zhu, MD, PhD, discusses the role of elective nodal irradiation in breast cancer and research efforts that may answer some remaining questions with this modality.

David Polsky, MD, PhD, discusses the development and clinical utility of biomarkers in melanoma.

Jeffrey S. Weber, MD, PhD, discusses the activity of targeted therapy in metastatic melanoma, its adoption into the adjuvant setting, and the optimal use of immunotherapy in the space.

Howard A. "Skip" Burris, III, MD, FACP, FASCO, discusses the progress that has been made in metastatic triple-negative breast cancer and the work being done to broaden the utility of novel approaches.

The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.

The FDA has granted a priority review designation to a supplemental new drug application for rucaparib for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer.

The National Institute for Health and Care Excellence has recommended the use of olaparib as a maintenance treatment in adults with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The FDA has granted a priority review designation to a supplemental biologics license application for the combination of nivolumab and ipilimumab for the first-line treatment of patients with metastatic or recurrent non–small cell lung cancer that does not have EGFR or ALK genomic tumor aberrations.

Stephanie L. Graff, MD, discusses the importance of using genomic risk to tailor treatment to patients with early-stage hormone receptor-positive, HER2-negative disease, the benefit of extended endocrine therapy, and ongoing research with CDK4/6 inhibitors and immunotherapy.

Nancy U. Lin, MD, discusses research focusing on CNS penetration in HER2-positive metastatic breast cancer.

Treatment with luspatercept-aamt reduced the severity of anemia in patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions.

Atif Hussein, MD, discusses how the treatment of patients with hepatocellular carcinoma and cholangiocarcinoma has evolved in recent years.

Erika P. Hamilton, MD, discusses research presented at the 2019 San Antonio Breast Cancer Symposium and how the data are impacting the treatment of patients with HER2-positive breast cancer.

Denise Yardley, MD, discusses the implications of CDK4/6 inhibitors in hormone receptor-positive/HER2-negative breast cancer. 

The first-line combination of sintilimab injection plus pemetrexed and platinum-based therapy showed a statistically significant improvement in progression-free survival compared with chemotherapy and placebo in patients with advanced or recurrent nonsquamous non–small cell lung cancer who did not harbor EGFR or ALK abnormalities, according to an interim analysis of the phase III ORIENT-11 trial.